More importantly, high levels of miR-762 predisposed the NSCLC patients receiving EGFR-TKIs chemotherapy to a significantly shorter progression-free survival and overall survival time (Fig. 6). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.